| Literature DB >> 26539412 |
L'ubomíra Tóthová1, Natália Kamodyová2, Tomáš Červenka2, Peter Celec3.
Abstract
Saliva is an interesting alternative diagnostic body fluid with several specific advantages over blood. These include non-invasive and easy collection and related possibility to do repeated sampling. One of the obstacles that hinders the wider use of saliva for diagnosis and monitoring of systemic diseases is its composition, which is affected by local oral status. However, this issue makes saliva very interesting for clinical biochemistry of oral diseases. Periodontitis, caries, oral precancerosis, and other local oral pathologies are associated with oxidative stress. Several markers of lipid peroxidation, protein oxidation and DNA damage induced by reactive oxygen species can be measured in saliva. Clinical studies have shown an association with oral pathologies at least for some of the established salivary markers of oxidative stress. This association is currently limited to the population level and none of the widely used markers can be applied for individual diagnostics. Oxidative stress seems to be of local oral origin, but it is currently unclear whether it is caused by an overproduction of reactive oxygen species due to inflammation or by the lack of antioxidants. Interventional studies, both, in experimental animals as well as humans indicate that antioxidant treatment could prevent or slow-down the progress of periodontitis. This makes the potential clinical use of salivary markers of oxidative stress even more attractive. This review summarizes basic information on the most commonly used salivary markers of oxidative damage, antioxidant status, and carbonyl stress and the studies analyzing these markers in patients with caries or periodontitis.Entities:
Keywords: antioxidant status; biomarkers; oral diseases; oxidative stress; saliva
Mesh:
Substances:
Year: 2015 PMID: 26539412 PMCID: PMC4611854 DOI: 10.3389/fcimb.2015.00073
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Association studies investigating salivary markers of oxidative stress and dental caries.
| 82 consecutive pediatric dental patients | AOPP (SPH), TBARS (SFL), AGES (SFL), FRAP (SPH), TAC (SPH) | Children with CI: 0, AOPP (160 μmol/L | AOPP were related to CI (eta 8.6%, | Tóthová et al., |
| 50 children with severe early childhood caries (S-ECC), 50 healthy control children | TAC (SPH) | Control children, TAC (0.568 ± 0.169 mmol/L); | ↑ TAC in children with S-ECC ( | Kumar et al., |
| 80 children, 8 groups—according to age, gender and caries activity ( | TAC (SPH) | Girls, age 7–10, caries free, TAC (0.39 ± 0.08 mmol/L); | ↑ TAC in caries active groups ( | Tulunoglu et al., |
| 120 children, 8 groups—according to age, gender and caries activity ( | TAC (SPH) | Girls, age 7–10, caries free, TAC (0.16 ± 0.03 μmol/L); | ↑ TAC in children with caries in comparison to children without caries ( | Preethi et al., |
| 126 children (4.5–14.5 years), caries in deciduous teeth (78.6% of children), caries in permanent teeth (77.8% of children) | TAC (SPH) | Caries free in deciduous teeth, TAC (7.8 ± 4.0 1/IC50); caries free in permanent teeth, TAC (7.8 ± 5.0 1/IC50); caries active in deciduous teeth, TAC (10.6 ± 11.1 1/IC50); caries active in permanent teeth, TAC (9.0 ± 8.0 1/IC50) | ↑ TAC in patients with caries in deciduous teeth than among those without caries (p=0.06); linear regression between the number of deciduous teeth affected by caries and TAC ( | Uberos et al., |
| 100 children, 4 groups—with early childhood caries and controls (below 71 months), with rampant caries and controls (6–12 years) | TAC (SPH) | Early childhood caries | ↑ TAC in children with caries ( | Hegde et al., |
| 80 children, (aged 3–5 years), 2 groups—with severe early childhood caries and controls ( | FRAP (SPH) | N/A | ↑ FRAP in children with severe early childhood caries ( | Mahjoub et al., |
| 50 children, (aged 3–5 years), 2 groups—with severe early childhood caries and controls ( | TAC (SPH) | Severe early caries, TAC (1.82 ± 0.19 mmol/l saliva); Control group TAC (1.08 ± 0.17 mmol/l saliva) | ↑ TAC in children with severe early childhood caries ( | Muchandi et al., |
| 100 healthy high school students (age 15–17 years), 4 groups according to gender and caries activity. (Caries active was confirmed when volunteer had at least 5 caries surfaces) | TAC (SPH) | Boys, caries active TAC (59.72 ± 12.15); | ↑ TAC in caries active males when compared to caries free males ( | Ahmadi-Motamayel et al., |
| 21 adult patients with caries, 16 controls | GSH (SPH), LPO (SPH) | Caries group, GSH (1.6 ± 0.75 mg/g protein), LPO (0.3 ± 0.15 μmol MDA/g protein); | ↓ GSH in caries group ( | Oztürk et al., |
| 67 adult patients with dental caries, 50 controls | TBARS (SPH) | Females, caries free, MDA (3.24 ± 0.54 ng/mL); | ↑ MDA in caries active patients ( | Rai et al., |
| 100 adult patients, 4 groups ( | TAC (SPH) | Control group, TAC (0.34 ± 0.13 μmol/L); | ↑ TAC was observed in groups with higher DMFT score ( | Hegde et al., |
TAC, total antioxidant capacity; AOPP, advanced oxidation protein products; TBARS, thiobarbituric acid reacting substances; AGES, advanced glycation end products; FRAP, ferric reducing antioxidant power; GSH, reduced glutathione; LPO, lipid peroxidation; SPH, spectrophotometry; SFL, spectrofluorometry;
denotes levels estimated from graph.
Association studies investigating salivary markers of oxidative stress and periodontal diseases.
| 36 CP patients, 28 controls | MDA (HPLC), TOS (SPH) | Control group, MDA (median 0.06 μM), TOS (4.16 ± 0.63 mM H2O2 Equivalent); | ↑ MDA and ↑ TOS in CP patients ( | Akalin et al., |
| 30 CP patients (15 smokers), 30 controls (15 smokers) | MDA (SFL), GSHPx (SPH), TAC (PCL) (baseline and 6 moth after non-surgical treatment) | Control group, non-smokers, MDA (0.065 ± 0.05 μmol/L), GSHPx (5.78 ± 3.77 U/L), TAC flow rate (0.52 ± 0.20 μmol/mL); | ↑ MDA in smoking CP patients compared to non-smoking controls ( | Guentsch et al., |
| 48 CP patients, 35 controls | MDA (HPLC), TOS (SPH), SOD (SPH) (baseline and 16 weeks after non-surgical treatment) | Control 1, MDA (0.10 ± 0.02 mM), TOS (6.75 ± 1.02 mM), SOD (174.9 ± 21.07 U/mg protein); | ↑ TOS and ↑ SOD in CP group ( | Wei et al., |
| 74 patients with periodontitis, 3 groups -early ( | MDA (SPH) | Control group, MDA (5.16 ± 0.03 μmol/mL) Early periodontitis group, MDA (28.08 ± 1.56 μmol/mL); | Significant differences in MDA levels of patients with early, moderate and severe periodontitis in comparison to control patients ( | Khalili and Biloklytska, |
| Preliminary study: 13 CP patients, 9 controls | GSH (SPH), GPx (SPH), LPO (SPH) | Preliminary stud Control group, GSH (606.67 ± 191.02 μmol/L), GPx (92.90 ± 58.58 mU/mL), LPO (0.13 ± 0.08 μmol/L); | ↓ GSH ( | Tsai et al., |
| Subsequent study: 22 CP patients | Subsequent study: (baseline and 1 month after initial periodontal treatment) | Periodontitis group, GSH (373.04 ± 287.42 μmol/L), GPx (92.99 ± 74.40 mU/mL), LPO (0.66 ± 0.36 μmol/L) | ||
| 217 consecutive stomatologic patients | TBARS (SFL), MDA (HPLC) | TBARS (0.05–2.2 μmol/L | ↑ TBARS tightly associated with ↑ PBI (adjusted for age and sex, | Celec et al., |
| 204 consecutive stomatologic patients | TBARS (SPH), AOPP (SPH), TAC (SPH), AGEs (SFL) | Group with PBI = 0, TBARS (0.038 μmol/L | TBARS associated with PBI ( | Celecová et al., |
| 82 consecutive pediatric dental patients | AOPP (SPH), TBARS (SFL), AGES (SFL), FRAP (SPH), TAC (SPH) | Children with PBI: 0, AOPP (140 μmol/L | variability of PBI explains 10.9% of the variance of TBARS ( | Tóthová et al., |
| 29 periodontitis patients, 20 controls | 8-HOdG (C-ELISA kit) (baseline and 2–4 month after initial periodontal treatment) | Control group, 8-HOdG (1.48 ± 0.08 ng/mL) Periodontitis group, 8-HOdG (4.36 ± 0.18 ng/mL) | ↑ 8-HOdG in periodontitis patients ( | Sawamoto et al., |
| 24 patients with periodontitis, 3 groups—early ( | TBARS (SPH), TAP (SPH), cAMP (ELISA), cGMP (ELISA) | Control group, TBARS (1.2 μmol/mL | ↓ cAMP and ↓ cGMP in patients with moderate and advanced periodontitis ( | Mashayekhi et al., |
| 58 periodontitis patients, 234 controls | 8-OHdG (ELISA), 8-epi-PGF2α (ELISA), total protein carbonyls (ELISA), TAC (SPH) | Control group, 8-OHdG (42.65 ng/ml), 8-epi-PGF2α (43.57 pg/ml), protein carbonyls (0.96 nmol/mg protein), TAC (0.46 mM); | ↑ 8-OHdG ( | Su et al., |
| 16 patients with stage I periodontitis, 16 patients with stage II periodontitis, 15 controls | MDA, ceruloplasmin (detailed methods not provided) | Control group, MDA (0.58 ± 0.14 nmol/mL), ceruloplasmin (3.46 ± 1.25 mg%); | ↑ MDA in patients with stage I and stage II periodontitis in comparison to control ( | Dalai et al., |
| 20 CP patients, 20 controls | 8-HOdG (ELISA), MDA (SPH), uric acid (SPH), TAC (SPH), GPx (SPH) | Control group, 8-HOdG (6.46 ± 0.93 ng/mg albumin), MDA (0.25 ± 0.4 nmol/mg albumin), uric acid (3.12 ± 0.85 mg/mg albumin), TAC (1.24 ± 0.16 nmol/mg albumin), GPx (28.16 ± 11.95 U/mg albumin); | 8-OHdG, MDA higher in CP group ( | Miricescu et al., |
| 32 patients with periodontits, 32 control patients | 8-OHdG (C-ELISA kit) | Control group, 8-OHdG (1.41 ± 0.22 ng/ml) | ↑ 8-OHdG in patients with periodontitis ( | Canakçi et al., |
| 78 patients with periodontitis, 17 controls | 8-HOdG (ELISA) | Control group, 8-OHdG (1.56 ± 0.10 ng/mL); | ↑ 8-HOdG in patients with periodontitis ( | Takane et al., |
| 20 CP patients, 20 CG patients, 20 controls | 8-HOdG (C-ELISA) | Control group, 8-OHdG (1.56 ± 0.12 ng/mL) | ↑ 8-HOdG in CP than in CG and H groups ( | Sezer et al., |
| 34 CP patients, two groups- with periodontally involved teeth of hopeless prognosis ( | 8-OHdG (C-ELISA) (baseline and 2–6 months after initial periodontal treatment) | Control group, 8-OHdG (1.56 ± 0.1 ng/mL) | ↑ 8-OHdG in those with than in subjects without periodontally-involved teeth of hopeless prognosis ( | Takane et al., |
| 24 patients with CP, 24 controls | 8-OHdG (baseline and 10 days, 1 month, 3 months after initial periodontal therapy) | CP baseline 8-OHdG (605.5 ± 139.1) controls 8-OHdG (550.52 ± 150.28) | salivary 8-OHdG did not differ between groups or during initial periodontal therapy ( | Dede et al., |
| 129 patients, cohort study | TAC (SPH), ascorbate (SPH), urate (SPH), albumin (SPH), protein carbonyl (SPH) | Men, protein carbonyl (8.46 ± 1.71 fmol/g of protein), TAC flow rate (0.31 ± 0.02 μmol/mL/min), ascorbate flow rate (4.27 ± 0.44 nmol/mL/min), albumin flow rate (5.44 ± 0.74 nmol/mL/min), urate flow rate (108.8 ± 12.0 nmol/mL/min); | ↓ TAC in women than in men ( | Sculley and Langley-Evans, |
| 17 patients with severe periodontitis, 20 controls | Uric acid (SPH), albumin (SPH), ascorbic acid (SPH), TAC (SPH) | Control group, uric acid (160 μmol/L | ↓ TAC in patients with periodntitis ( | Diab-Ladki et al., |
| 20 CP patients, 20 controls | TAC (ECL) | Control group, TAC (0.14 ± 0.06 nmoles/30 s sample) | ↓TAC in CP group than in control group ( | Brock et al., |
| 18 patients with periodontitis, 16 controls | TAC (ECL) | Control group, TAC (254 ± 110 mumol/L); Peridontitis group, TAC (175 ± 53 mumol/L) | ↓ TAC in the peridontitis patients than in control patients ( | Chapple et al., |
| 24 patients with gingivitis, 23 with periodontitis, and 23 controls | SOD (SPH), thiol antioxidant concentrations (SPH) (baseline and 15 days after non-surgical treatment) | Before treatment: | ↑ SOD and thiol concentrations post-treatment in all the three groups, comparison between the three groups post-treatment did not show any significant difference in improvement of superoxide dismutase or thiol concentrations | Karim et al., |
| 21 CP patients | GPx, SOD, albumin, uric acid, total antioxidative status (TAS) (before and after non-surgical treatment) | N/A | ↑ uric acid, albumin, GPx, TAS; ↓ SOD activity after treatment; correlation between GPx and plaque index, SOD and gingival index before therapy; correlation between SOD and bleeding on probing, and TAS and bleeding on probing after therapy | Novakovic et al., |
| 23 CP patients (14 females, 9 males) | TBARS, AGEs (SFL), TAC FRAP (SPH) | N/A | ↑ TBARS in male CP ( | Banasová et al., |
| 19 controls (8 females, 11 males) | ||||
| 30 CP patients 30 controls | MDA, SOD, GR, CAT (all markers SPH) | CP group MDA (9.34 ± 8.15 nmol/ml), SOD (19.76 ± 11.53 U/ml), CAT (0.08 ± 0.13 U/min/mg prot), GR (12.51 ± 6.39 U/min/mg prot); | ↑ MDA in CP; ↓ SOD, CAT and GR in CP compared to control group Positive correlation between MDA and periodontal status; Negative correlation between SOD, CAT and GR and periodontal status | Trivedi et al., |
| 30 CP patients with diabetes mellitus type 2 | SOD | CP group MDA (9.09 ± 8.16 nmol/ml) SOD (19.93 ± 12.05 U/ml) | ↑ MDA in CP irrespective of diabetes; | Trivedi et al., |
| 30 CP patients without systemic disease | CAT | GR (13.63 ± 6.46 U/min/mg prot) CAT (0.08 ± 0.14 U/min/mg prot) | SOD and GR differed in CP patients with diabetes mellitus type 2 compared to CP without systemic disease | |
| 30 controls with diabetes mellitus type 2 | CP group with DM type 2 MDA (10.79 ± 8.07 nmol/ml) | |||
| 33 CP patients | MDA (HPLC) | CP group MDA 0.15 μmol/L (0.1 to 0.18), TOS 6.32 μmol/L (5.51 to 7), TAC (0.53 ± 0.11 mmol/L); | ↓ TAC ↑ MDA, TOS and oxidation stress index in CP and GAP in comparison with controls | Baltacioglu et al., |
| 47 CP patients (24 smokers, 23 non-smokers) | 8-OHdG, 4-HNE, GPx (ELISA) | Smokers with CP 8-OHdG (8.02 ng/ml ± 1.46), 4-HNE (144.28 pg/ml ± 59.18), GPx (36.81 U/ml ± 9.16) | ↑ 8-OHdG in patients with CP (irrespective of smoking) compared to controls; | Hendek et al., |
| 46 controls (23 smokers, 23 non-smokers) | Smokers controls 8-OHdG (7.50 ng/ml ± 1.46), 4-HNE (131.40 pg/ml ± 23.03), GPx (29.22 U/ml ± 16.45) | |||
| 30 CP (baseline, 1 month after periodontal treatment) 30 controls | 8-OHdG (ELISA) | 8-OHdG CP group (645.18 pg/ml ± 84.91), control group (527.23 pg/ml ± 62.19) after treatment 8-OHdG CP group (532.18 pg/ml ± 91.37) | ↑ 8-OHdG in patients with CP; ↓ 8-OHdG after treatment | Arunachalam et al., |
| 23 CP (8 females, 15 males) 25 controls (15 females, 10 males); (baseline, 6 weeks after periodontal treatment) | 8-OHdG (ELISA and LC-MS/MS) | N/A | ↓ 8-OHdG after treatment; correlation between plaque index, gingival index, probing pocke depth, clinical attachment level, bleeding on probing | Kurgan et al., |
| 31 CP patients baseline and after periodontal treatment | TAC (SPH) | TAC before treatment (0.655 μmol/L ± 0.281) | ↑ TAC after periodontal treatment | Shirzaiy et al., |
| CP patient | NO (SPH) | CP NO (16.53 ± 1.51) | ↑ NO in both periodontal groups compared to controls positive correlation of NO and periodontal parameters in both groups of patients | Sundar et al., |
| 89 generalized severe CP patients, 56 healthy controls (non-smokers); both gender | NO metabolites (SPH) | Only graphs available | ↓ NO in CP compared to healthy controls | Andrukhov et al., |
| CP patients divided into 2 groups according smoking status and healthy controls ( | NO (SPH) | Non-smoking CP NO (79.52 μmol/L ± 24.88) | ↑ NO in both periodontal groups compared to controls; smoking significantly effects NO levels | Wadhwa et al., |
| Patients with gingivitis periodontits and controls ( | Nitrite | Gingivitis group nitrite (79.64 ± 4.62) | ↑ NO in gingivitis and periodontitis patients compared to controls | Poorsattar Bejeh-Mir et al., |
| Patients with gingivitis periodontits and controls ( | NO (SPH) | Gingivitis group | ↑ NO in gingivitis and periodontitis patients compared to controls | Parwani et al., |
| Rapidly progressive periodontitis, adult periodontitis and healthy controls ( | NO2(SPH) | Progressive periodontitis group NO2(2.5 ± 3.27 μmol/l) | ↓ NO2 in CP patients compared to healthy controls; patiemts with rapidly progresive perriodontitis had ↓ NO2compared to patients with adult form of periodontitis | Aurer et al., |
CP, chronic periodontitis; CG, chronic gingivitis; TAC, total antioxidant capacity; TAP, total antioxidant power; AOPP, advanced oxidation protein products; TBARS, thiobarbituric acid reacting substances; AGES, advanced glycation end products; FRAP, ferric reducing antioxidant power; 8-HOdG, 8-hydroxydeoxyguanosine; 8-epi PGF2α, 8-epi prostaglandin F2α; GPx, glutathione peroxidase; GSH, reduced glutathione; GR, glutathione reductase; MDA, malodialdehyde; LPO, lipid peroxidation; TOS, total oxidant status; SOD, superoxid dismutase; SPH, spectrophotometry; SFL, spectrofluorometry; PCL, photochemiluminescence; ECL, enhanced chemiluminescent assay; HPLC, high performance liquid chromatography; C-ELISA, competitive ELISA;
denotes levels estimated from graph.
Figure 1Potential for non-invasive use of salivary biomarkers associated with caries and periodontitis. Saliva can be used for disease screening, monitoring of progress, and treatment as well as in basic research on etiology or pathogenesis. 8-OHdG, 8-hydroxyguanosine; AOPP, advanced oxidation protein products; FRAP, ferric reducing antioxidant power; NO, nitric oxide; TAC, total antioxidant capacity; TBARS/MDA, thiobarbituric acid reacting substances/malondialdehyde; TOS, total oxidant status; SOD, superoxide dismutase.
Figure 2The origin of salivary markers of oxidative stress. Three possible sources are shown—blood plasma (A), oral bacteria (B), and immune cells (C). Although direct evidence is lacking, salivary markers of oxidative stress seem to be of local oral origin. At least in periodontitis the production of reactive oxygen species by oral bacteria or activated neutrophils seems to be of importance. In systemic diseases diffusion from plasma could be the main source of salivary markers of oxidative stress.